筋萎縮性側索硬化症（ALS）：グローバル製薬市場機会分析と予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 15
2.1 Catalyst 15
2.2 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 17
3.2 Symptoms 23
3.2.1 Prognosis and Diagnosis 24
3.2.2 Quality of Life 27
4 Epidemiology 28
4.1 Risk Factors and Comorbidities 28
4.2 Global Trends 30
4.2.1 US 30
4.2.2 5EU 31
4.2.3 Japan 33
4.3 Forecast Methodology 33
4.3.1 Sources Used 34
4.3.2 Sources Not Used 37
4.3.3 Forecast Assumptions and Methods, Incident Cases 38
4.4 Epidemiological Forecast for ALS (2013-2023) 41
4.4.1 Diagnosed Prevalent Cases of ALS 41
4.4.2 Age-Specific Incident Cases of ALS 42
4.4.3 Sex-Specific Diagnosed Prevalent Cases of ALS 44
4.4.4 Age-Standardized Diagnosed Prevalence of ALS 46
4.5 Discussion 48
4.5.1 Epidemiological Forecast Insight 48
4.5.2 Limitations of the Analysis 48
4.5.3 Strengths of the Analysis 49
5 Current Treatment Options 50
5.1 Overview 50
5.2 Product Profiles – Major Brands 53
5.2.1 Rilutek (riluzole) 53
6 Unmet Needs Assessment and Opportunity Analysis 57
6.1 Overview 57
6.2 Unmet Needs Analysis 59
6.2.1 Therapies That Can Slow or Halt Disease Progression 59
6.2.2 Appetite-Stimulating Agents 59
6.2.3 Preservation of Muscle Strength/Mobility 60
6.2.4 Biomarkers for Diagnosis/Staging 60
6.2.5 Treatments for Sialorrhea 61
6.2.6 Protection of Cognitive Function 62
6.2.7 Relief of Spasticity, Cramps, and Pain 63
6.2.8 Extending Patient Survival 63
6.2.9 Increasing Patient Function 63
7 Research and Development Strategies 65
7.1 Overview 65
7.1.1 Anti-Glutamate Agents 65
7.1.2 Antioxidants and Mitochondrial Preservation 67
7.1.3 Growth Factors 67
7.1.4 Anti-Apoptosis 68
7.1.5 Immunosuppression 69
7.1.6 Protein Aggregation 70
7.2 Clinical Trial Design 71
8 Pipeline Assessment 73
8.1 Overview 73
8.2 Drugs in Late-Stage Clinical Development 73
8.2.1 AB-1010 (masitinib) 74
8.2.2 Radicut (edaravone) 77
8.2.3 Methycobal (mecobalamin) 80
8.2.4 Arimoclomol 82
8.2.5 CK-2017357 (CK-357, tirasemtiv) 84
8.3 Innovative Early-Stage Approaches 88
9 Pipeline Valuation Analysis 90
9.1 Clinical Benchmarks of Key Pipeline Drugs 91
9.2 Commercial Benchmarks of Key Pipeline Drugs 93
9.3 Competitive Assessment 94
9.4 Top-Line Five-Year Forecast 96
9.4.1 US 98
9.4.2 5EU 99
9.4.3 Japan 100
10 Appendix 103
10.1 Bibliography 103
10.2 Abbreviations 118
10.3 Methodology 122
10.4 Forecast Methodology 122
10.4.1 Diagnosed and Treated ALS Patients 124
10.4.2 Launch and Patent Expiry Dates 124
10.4.3 General Pricing Assumptions 125
10.4.4 Individual Drug Assumptions 126
10.4.5 Generic Erosion 128
10.4.6 Pricing of Pipeline Agents 129
10.5 Physicians and Specialists Included in This Study 130
10.6 About the Authors 131
10.6.1 Author 131
10.6.2 Epidemiologist 132
10.6.3 Global Head of Healthcare 132
10.7 About GlobalData 133
10.8 Disclaimer 133